Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Midori Kjellin, Hege Kileng, Dario Akaberi, Navaneethan Palanisamy, Ann-Sofi Duberg, Astrid Danielsson, Magnhild Gangsøy Kristiansen, Johan Nöjd, Soo Aleman, Tore Gutteberg, Rasmus Goll, Anders Lannergård & Johan Lennerstrand. (2019) Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scandinavian Journal of Gastroenterology 54:8, pages 1042-1050.
Read now
Read now
Claudia Minosse, Marina Selleri, Emanuela Giombini, Barbara Bartolini, Maria Rosaria Capobianchi, Stefano Cerilli, Laura Loiacono, Chiara Taibi, Gianpiero D’Offizi, Fiona McPhee & AnnaRosa Garbuglia. (2018) Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents. Infection and Drug Resistance 11, pages 2117-2127.
Read now
Read now
Hege Kileng, Midori Kjellin, Dario Akaberi, Assar Bergfors, Ann-Sofi Duberg, Lars Wesslén, Astrid Danielsson, Magnhild Gangsøy Kristiansen, Tore Gutteberg, Rasmus Goll, Anders Lannergård & Johan Lennerstrand. (2018) Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014–2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy. Scandinavian Journal of Gastroenterology 53:10-11, pages 1347-1353.
Read now
Read now
Articles from other publishers (28)
Andrea Galli & Jens Bukh. 2023. Viral Fitness and Evolution. Viral Fitness and Evolution
237
264
.
Petra Simicic, Anamarija Slovic, Leona Radmanic, Adriana Vince & Snjezana Zidovec Lepej. (2022) Molecular Epidemiology and Baseline Resistance of Hepatitis C Virus to Direct Acting Antivirals in Croatia. Pathogens 11:7, pages 808.
Crossref
Crossref
Gail V. Matthews, Sanjay Bhagani, Marc Van der Valk, Juergen Rockstroh, Jordan J. Feld, Andri Rauch, Christine Thurnheer, Julie Bruneau, Arthur Kim, Margaret Hellard, David Shaw, Ed Gane, Mark Nelson, Patrick Ingiliz, Tanya L. Applegate, Jason Grebely, Phillipa Marks, Marianne Martinello, Kathy Petoumenos, Gregory J. Dore, Marc van der Valk, Margaret Hellard, Ed Gane, Andri Rauch, Julie Bruneau, Arthur Kim, Sanjay Bhagani, Greg Dore, Pip Marks, Gail Matthews, Jason Grebely, Kathy Petoumenos, Marianne Martinello, Tanya Applegate, Jordan Feld, Jürgen Rockstroh, Gail Matthews, Pip Marks, Sophia Amjad, Elise Tu, Kathy Petoumenos, Mahshid Tamaddoni, Marc van der Valk, Margaret Hellard, Ed Gane, Maria Christine Thurnheer, Yvonne Gilleece, Julie Bruneau, Mark Nelson, Chris Fraser, Alberto Moriggia, Thomas Lutz, Juhi Moon, Phillip Read, Arthur Y. Kim, Andrew Ustianowski, Christiane Cordes, David Shaw, Sanjay Bhagani, Joe Sasadeusz, Mark Hull, Greg Dore, Jordan Feld, Jürgen Rockstroh, Dominique Braun & Patrick Ingiliz. (2021) Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. Journal of Hepatology 75:4, pages 829-839.
Crossref
Crossref
Zhenqiu Liu, Xianhua Mao, Jiaqi Wu, Kangkang Yu, Qin Yang, Chen Suo, Ming Lu, Li Jin, Tiejun Zhang & Xingdong Chen. (2021) World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents. Clinical Gastroenterology and Hepatology 19:9, pages 1906-1914.e25.
Crossref
Crossref
Claudia Minosse, Cesare E. M. Gruber, Martina Rueca, Chiara Taibi, Mauro Zaccarelli, Elisabetta Grilli, Marzia Montalbano, Maria R. Capobianchi, Andrea Antinori, Gianpiero D’Offizi, Fiona McPhee & Anna Rosa Garbuglia. (2021) Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses 13:6, pages 1151.
Crossref
Crossref
Nadia Marascio, Angela Costantino, Stefania Taffon, Alessandra Lo Presti, Michele Equestre, Roberto Bruni, Giulio Pisani, Giorgio Settimo Barreca, Angela Quirino, Enrico Maria Trecarichi, Chiara Costa, Maria Mazzitelli, Francesca Serapide, Giovanni Matera, Carlo Torti, Maria Carla Liberto & Anna Rita Ciccaglione. (2021) Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy. Journal of Clinical Medicine 10:8, pages 1655.
Crossref
Crossref
Marianne Martinello, Jasmine Yee, Sofia R Bartlett, Phillip Read, David Baker, Jeffrey J Post, Robert Finlayson, Mark Bloch, Joseph Doyle, David Shaw, Margaret Hellard, Kathy Petoumenos, Lanni Lin, Philippa Marks, Tanya Applegate, Gregory J Dore & Gail V Matthews. (2020) Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. Clinical Infectious Diseases 71:6, pages 1502-1510.
Crossref
Crossref
Marianne Martinello, Chloe Orkin, Graham Cooke, Sanjay Bhagani, Edward Gane, Ranjababu Kulasegaram, David Shaw, Elise Tu, Kathy Petoumenos, Philippa Marks, Jason Grebely, Gregory J. Dore, Mark Nelson & Gail V. Matthews. (2020) Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection. Hepatology 72:1, pages 7-18.
Crossref
Crossref
Mark W. Douglas, Enoch S.E. Tay, Dao Sen Wang, Adrian T.L. Ong, Caroline Wilson, Amy Phu, Jen Kok, Dominic E. Dwyer, Rowena A. Bull, Andrew R. Lloyd, Tanya L. Applegate, Gregory J. Dore, Anita Y. Howe, Richard Harrigan & Jacob George. (2020) Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. Hepatology Communications 4:6, pages 904-915.
Crossref
Crossref
Gregory J. Dore, Jordan J. Feld, Alex Thompson, Marianne Martinello, Andrew J. Muir, Kosh Agarwal, Beat Müllhaupt, Heiner Wedemeyer, Karine Lacombe, Gail V. Matthews, Michael Schultz, Marina Klein, Christophe Hezode, Gerard Estivill Mercade, Danny Kho, Kathy Petoumenos, Philippa Marks, Fernando Tatsch, Ana Gabriela Pires Dos Santos & Ed Gane. (2020) Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. Journal of Hepatology 72:3, pages 431-440.
Crossref
Crossref
Petra Simicic, Ivana Grgic, Maja Santak, Adriana Vince & Snjezana Zidovec Lepej. (2019) Frequency of baseline NS5A resistance-associated substitutions in patients infected with genotype 1 of hepatitis C virus in Croatia. Microbial Pathogenesis 136, pages 103694.
Crossref
Crossref
Heidar SharafiSaman Ghalamkari, Alireza HassanshahiSeyed Moayed Alavian. (2019) Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank. Microbial Drug Resistance 25:7, pages 1072-1079.
Crossref
Crossref
Adrian TL Ong, Enoch Tay, Dominic E Dwyer, Jacob George & Mark W Douglas. (2018) Pre-treatment Antiviral Resistance in Australians with Chronic Hepatitis C: Prevalence of NS3 and NS5A Resistance Data in the State of New South Wales. Antiviral Therapy 24:4, pages 281-290.
Crossref
Crossref
Heidar Sharafi, Saeideh Maleki & Seyed Moayed Alavian. (2019) Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. Virus Research 259, pages 54-61.
Crossref
Crossref
Navaneethan Palanisamy, Prabhav Kalaghatgi, Dario Akaberi, Åke Lundkvist, Zhi-wei Chen, Peng Hu & Johan Lennerstrand. (2017) Worldwide Prevalence of Baseline Resistance-Associated Polymorphisms and Resistance Mutations in HCV against Current Direct-Acting Antivirals. Antiviral Therapy 23:6, pages 485-493.
Crossref
Crossref
M.S. Pedersen, U. Fahnøe, T.A. Hansen, A.G. Pedersen, H. Jenssen, J. Bukh & K. Schønning. (2018) A near full-length open reading frame next generation sequencing assay for genotyping and identification of resistance-associated variants in hepatitis C virus. Journal of Clinical Virology 105, pages 49-56.
Crossref
Crossref
Nadia Marascio, Grazia Pavia, Isabella Romeo, Carmine Talarico, Sebastiano Di Salvo, Mariaconcetta Reale, Vito Marano, Giorgio Settimo Barreca, Fernanda Fabiani, Nicola Perrotti, Massimo De Siena, Francesca Giancotti, Tiziana Gravina, Stefano Alcaro, Anna Artese, Carlo Torti, Maria Carla Liberto & Alfredo Focà. (2018) Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling. Journal of Medical Virology 90:7, pages 1257-1263.
Crossref
Crossref
Marta Grandal, Berta Pernas, Andrés Tabernilla, Ana Mariño, Hortensia Álvarez, Nieves Valcarce, Alvaro Mena, Angeles Castro‐Iglesias, Ana B. Pérez, Manuel Delgado & Eva Poveda. (2018) Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies. Journal of Medical Virology 90:6, pages 1094-1098.
Crossref
Crossref
Navaneethan Palanisamy & Johan Lennerstrand. (2016) Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach. Interdisciplinary Sciences: Computational Life Sciences 10:1, pages 143-156.
Crossref
Crossref
Barbara Bartolini, Emanuela Giombini, Chiara Taibi, Raffaella Lionetti, Marzia Montalbano, Ubaldo Visco-Comandini, Gianpiero D’Offizi, Maria Rosaria Capobianchi, Fiona McPhee & Anna Rosa Garbuglia. (2017) Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents. Viruses 9:8, pages 212.
Crossref
Crossref
Sofia R. Bartlett, Jason Grebely, Auda A. Eltahla, Jacqueline D. Reeves, Anita Y.M. Howe, Veronica Miller, Francesca Ceccherini‐Silberstein, Rowena A. Bull, Mark W. Douglas, Gregory J. Dore, Patrick Harrington, Andrew R. Lloyd, Brendan Jacka, Gail V. Matthews, Gary P. Wang, Jean‐Michel Pawlotsky, Jordan J. Feld, Janke Schinkel, Federico Garcia, Johan Lennerstrand & Tanya L. Applegate. (2017) Sequencing of hepatitis C virus for detection of resistance to direct‐acting antiviral therapy: A systematic review. Hepatology Communications 1:5, pages 379-390.
Crossref
Crossref
Andreas Walker, Matthias Bergmann, Jennifer Camdereli, Rolf Kaiser, Nadine Lübke & Jörg Timm. (2017) A genotype independent, full-genome reverse-transcription protocol for HCV genotyping and resistance testing. Journal of Clinical Virology 91, pages 42-48.
Crossref
Crossref
Lan S. Wang, Lionel S. D'Souza & Ira M. Jacobson. (2016) Hepatitis C-A clinical review. Journal of Medical Virology 88:11, pages 1844-1855.
Crossref
Crossref
Nicola Coppola, Carmine Minichini, Mario Starace, Caterina Sagnelli & Evangelista Sagnelli. (2016) Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. Journal of Medical Virology 88:10, pages 1659-1671.
Crossref
Crossref
Sabrina Bagaglio, Andrea Andolina, Marco Merli, Caterina Uberti-Foppa & Giulia Morsica. (2016) Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. Viruses 8:4, pages 91.
Crossref
Crossref
Qian Chen, Irene Belmonte, Maria Buti, Leonardo Nieto, Damir Garcia-Cehic, Josep Gregori, Celia Perales, Laura Ordeig, Meritxell Llorens, Maria Eugenia Soria, Rafael Esteban, Juan Ignacio Esteban, Francisco Rodriguez-Frias & Josep Quer. (2016) New real-time-PCR method to identify single point mutations in hepatitis C virus. World Journal of Gastroenterology 22:43, pages 9604.
Crossref
Crossref
Dimas Alexandre Kliemann, Cristiane Valle Tovo, Ana Beatriz Gorini da Veiga, Angelo Alves de Mattos & Charles Wood. (2016) Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World Journal of Gastroenterology 22:40, pages 8910.
Crossref
Crossref
Cecilia Trucchi, Andrea Orsi, Cristiano Alicino, Laura Sticchi, Giancarlo Icardi & Filippo Ansaldi. (2016) State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. Journal of Immunology Research 2016, pages 1-19.
Crossref
Crossref